Evidence map›Paper›PMID 23430672›Full record

Trial reportClinical interventions in aging2013

Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders.

Maria D Pinazo-Durán, Carmen Galbis-Estrada, Sheila Pons-Vázquez, Jorge Cantú-Dibildox, Carla Marco-Ramírez, Javier Benítez-del-Castillo

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical interventions in aging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease.The Cochrane database of systematic reviews · 2019
    Pooled it
  2. Pooled it
  3. Systemic treatment for blepharokeratoconjunctivitis in children.The Cochrane database of systematic reviews · 2016
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Review
  13. Personalized Management of Dry Eye Disease: Beyond Artificial Tears.Clinical ophthalmology (Auckland, N.Z.) · 2022
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Maria D Pinazo-DuránOphthalmic Research Unit Santiago Grisolia, Department of Surgery/Ophthalmology, Faculty of Medicine, University of Valencia, Valencia, Spain. dolores.pinazo@uv.es
Carmen Galbis-Estrada
Sheila Pons-Vázquez
Jorge Cantú-Dibildox
Carla Marco-Ramírez
Javier Benítez-del-Castillo
Universitat de València · ESHospital Jerez Puerta del Sur · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWomen, and those older than 65 years of age, are particularly susceptible to dry eye disorders (DEDs). Inflammation is clearly involved in the pathogenesis of DEDs, and there is mounting evidence on the antioxidant and antiinflammatory properties of essential polyunsaturated fatty acids (EPUFAs).

objectiveTo analyze whether a combined formulation of antioxidants and long-chain EPUFAs may improve the evolution of DEDs.

methodsWe used a prospective study to address the relationship between risk factors, clinical outcomes, and expression levels of inflammation and immune response (IIR) mediators in human reflex tear samples. Participants included: (1) patients diagnosed with nonsevere DEDs (DED group [DEDG]); and (2) healthy controls (control group [CG]). Participants were randomly assigned to homogeneous subgroups according to daily oral intake (+S) or not (-NS) of antioxidants and long-chain EPUFAs for 3 months. After an interview and a systematized ophthalmic examination, reflex tears were collected simultaneously from both eyes; samples were later subjected to a multiplexed particle-based flow cytometry assay. A specific set of IIR mediators was analyzed. All data were statistically processed through the SPSS 15.0 software program.

resultsSignificantly higher expressions of interleukin (IL)-1β, IL6, and IL10 and significantly lower vascular endothelial growth factor expressions were found in the DEDG as compared to the CG. In the DEDG, significant negative correlations were detected between the Schirmer test and IL-1β, IL6, IL8, and vascular endothelial growth factor levels, and between the fluorescein breakup time with IL6 and IL8 levels. However, levels of IL-1β, IL6, and IL10 in tears were significantly lower in the DEDG+S versus the DEDG-NS and in the CG+S versus the CG-NS. Subjective symptoms of dry eye significantly improved in the DEDG+S versus the DEDG-NS.

conclusionIIR mediators showed different expression patterns in DED patients, and these patterns changed in response to a combined formulation of antioxidant and EPUFAs supplementation. Our findings may be considered for future protocols integrating clinical/biochemical data to help manage DED patients.

Indexed as

Dietary SupplementsAdultAgedAged, 80 and overAntioxidantsDry Eye SyndromesFatty Acids, Omega-3FemaleHumansInflammation MediatorsInterleukin-10Interleukin-1betaInterleukin-6MaleMiddle AgedProspective StudiesAntioxidantsFatty Acids, Omega-3Inflammation MediatorsInterleukin-10Interleukin-1betaInterleukin-6Vascular Endothelial Growth Factor Aagingcytokinesessential polyunsaturated fatty acidsnutraceuticstearswomen

Identifiers

PMID23430672
PMCPMC3573824
OpenAlexW2097958521

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.